The Life Sciences Marketing Playbook That Stalls Medtech

Key Takeaways

• Pharma markets to prescribers through pharmacy benefit managers. Medtech sells to clinicians through IDN procurement and VAC committees. The buyer architecture is entirely different.
• Running demand capture campaigns before market demand exists burns runway without generating commercial traction.
• Early-stage medtech needs clinical champion development, not pharma-style awareness spend.
• The indicators that predict Series B readiness are shortened education cycles and inbound referral requests from clinical champions, not impressions or CTR.
• Life sciences marketing strategy built for pharma assumes a formed market. Pre-traction medtech is category creation.

Life sciences marketing looks like one discipline. But pharma life sciences marketing and early-stage medtech life sciences marketing are solving fundamentally different problems. Pharma steals share in a formed market.

Early-stage medtech creates a category that does not fully exist yet. The playbooks are not interchangeable, and founders who apply the pharma version before they have commercial traction burn the runway that should fund their Series B.

I've watched this play out on 370+ episodes of The State of MedTech. And I watched it up close before that, as a clinical sales rep at Mazor Robotics.

The founders who struggled most didn't lack clinical data or market size. They had a life sciences marketing strategy built for a different market structure.

Why Pharma Life Sciences Marketing Cannot Transfer to Early Stage Medtech

Pharma markets to prescribers. The purchase decision runs through pharmacy benefit managers, formularies, and payors. The buyer is not the user. The end goal is to get the drug on a formulary and then influence prescribing behavior at scale.

So pharma life sciences marketing builds awareness campaigns. It targets physician prescribers with broad messaging. It runs at scale because the market already exists. Every doctor knows what diabetes is, what hypertension is, what they're treating. The job is to steal share from the incumbent drug.

Medtech is different at every layer.

In early-stage medtech, the buyer is a clinician who is also the user. But that clinician does not act alone. The purchase goes through IDN procurement, a VAC committee, and often a GPO contract before anything gets approved.

And the market does not always exist yet. You may be creating the category, which means the clinician first has to understand that a problem they've always managed one way can now be solved differently.

That is a market formation problem. Running awareness campaigns at a market formation problem is like buying a bigger fishing net before the fish are in the water.

For context on how this shapes commercial strategy from the ground up, the medtech commercialization strategy post covers the structural model in depth.

How Running Demand Capture Campaigns Too Early Burns Medtech Commercial Runway

Demand capture assumes a formed market. The prospect already knows they have a problem and is searching for a solution. They're comparing options, evaluating vendors, deciding.

That is not pre-traction medtech.

In early-stage medtech, most potential customers do not yet know that your solution is possible. Many founders deploy SEO content, PPC, and awareness campaigns. All of these target the small percentage of prospects already in evaluation mode.

But you haven't built that evaluation market yet. So you spend heavily. You get impressions. You get some website traffic. And you get almost no commercial traction, because you've captured what little demand exists while doing nothing to create new demand.

The correct move is clinical champion development. Find the three to five physicians who will use the device, document outcomes, and bring it to their IDN procurement committee. Build the pull signal before you build the awareness campaign. Most pre-traction medtech companies have this sequence inverted.

Why Awareness Spend Fails When Early Medtech Needs Clinical Champion Development

I interviewed Brent Lavin, Director of Strategic Growth at BD, on an episode about how a billion-dollar M&A machine drives medtech growth. He was talking about acquisition targets, but the principle maps directly to life sciences marketing strategy:

"Too many med device companies take this farmer approach, trying to be everything for anybody. It's just the wrong idea."

That is the awareness spend problem described from a different angle. When you build broad life sciences marketing campaigns before identifying your clinical champion profile, you're farming a field without knowing what grows there.

The outcome that moves investors before Series B is not market reach. It's proof that a specific clinician type, in a specific facility type, will adopt, use, and champion the device. That is a pull signal. Broad awareness spend does not generate pull signals.

The medical device go-to-market strategy post breaks down how clinical champion development translates into commercial momentum at each stage of a medtech launch.

How Measuring Impressions Instead of Commercial Signals Keeps Founders From Series B

Most life sciences marketing agencies report on impressions, CTR, and social reach. Those are campaign performance metrics. They do not measure commercial traction.

The indicators that predict Series B readiness look different. How many inbound referral requests are you getting from clinical champions introducing the device to colleagues? Is your physician education cycle shortening? Did the three-hour dinner symposium you needed at launch compress to a forty-five-minute clinical conversation?

Are procurement timelines getting shorter at accounts where you've placed champions?

Those are lagging commercial signals. They show demand being pulled through the market, not pushed into it. And they are the signals that move investors from "interesting" to "I want to lead this round."

If your life sciences marketing strategy reporting doesn't include these indicators, you're measuring campaign activity and not commercial traction.

What Pull-Driven Life Sciences Marketing Strategy Looks Like Before Medtech Has Traction

Bruce Cleveland, whose venture firm invested in life sciences and technology companies for 15 years, described the structural problem on an episode of The State of MedTech focused on market engineering.

He said medtech always faces a two-phase problem: first, clear the FDA. Then, clear the market. Most companies spend disproportionately on FDA-phase tactics and enter the commercial phase without the infrastructure to generate pull.

The life sciences marketing strategy that works in pharma is optimized for the post-market phase. It assumes demand exists. And it has nothing to offer the market-clearing phase, where demand has to be engineered.

Market engineering for pre-traction medtech runs in a specific order. The market narrative comes first. Not a product pitch, but a category argument: why does this problem need a new solution, why now, and why is the existing alternative no longer acceptable.

Then clinical champion development, targeting innovators rather than the early majority. Then the evidence architecture investors recognize: peer-reviewed outcomes, conference presentations by your champions, and inbound interest from their clinical peers.

That sequence generates pull-driven demand. And pull-driven demand is what gets a Series B done.

What This Means for Medtech Founders

In my experience working with medtech founders, this problem surfaces the same way almost every time. The founder has solid clinical data, a couple of physician champions, and a sense that the market should be moving faster.

They hire a life sciences marketing agency. The agency delivers what it knows: campaigns built for pharma clients or commercial-stage medtech.

Three months in, the dashboard looks active. Impressions are up. Website traffic is up. And the investors are still saying the same thing: "Come back when you have traction."

The gap is structural. Pharma life sciences marketing is optimized for share capture in a formed market. Pre-traction medtech needs market engineering: the deliberate work of building the category, developing clinical conviction, and generating the pull signals that lead investors to yes.

FDA clearance is the starting line, not the finish line. The commercial work that follows requires a life sciences marketing strategy that matches your market formation stage, not the market capture stage your agency knows how to run.

Frequently Asked Questions

What Is Life Sciences Marketing?

Life sciences marketing is the discipline of creating awareness, generating demand, and driving commercial adoption for products in pharmaceutical, biotechnology, and medical device markets. It covers brand positioning, clinical education, regulatory messaging, and the commercial strategies that connect life sciences innovations with the buyers, prescribers, and institutions that adopt them.

How Is Life Sciences Marketing Different for Medtech Versus Pharma?

Pharma life sciences marketing targets prescribers in a formed market, where the goal is to influence prescribing behavior and capture market share from established drugs.

Medtech life sciences marketing at the pre-traction stage requires building a new category, identifying clinical champions, and navigating IDN and VAC procurement rather than pharmacy benefit channels. The buyer, the purchase mechanism, and the market formation stage are all different.

What Does Effective Life Sciences Marketing Look Like at the Pre-Traction Stage?

Effective pre-traction life sciences marketing focuses on clinical champion development rather than broad awareness. It identifies the three to five physician innovators who will adopt the device, document outcomes, and champion it through their institution's procurement process.

The goal is generating pull-driven demand, meaning inbound clinical peer interest, rather than awareness campaigns that assume a formed market.

What Are the Biggest Life Sciences Marketing Mistakes Early-Stage Medtech Companies Make?

The three most common mistakes are running demand capture campaigns before the market has formed, using awareness spend when the product needs clinical champion development, and measuring campaign vanity metrics like impressions and CTR instead of commercial signals like shortened education cycles and inbound referral requests. All three reflect applying a pharma playbook to a market-engineering problem.

Listen to Brent Lavin's Full Conversation

Brent Lavin's full conversation with Omar Khateeb is available on The State of MedTech. Watch on YouTube. Subscribe wherever you listen to podcasts.

About Brent Lavin

Brent Lavin is the Director of Strategic Growth at BD (Becton, Dickinson and Company), where he leads commercial growth strategy, identifying high-potential opportunities for organic development and targeted acquisitions.

BD is one of the world's largest medical technology companies, with operations spanning diagnostics, medication management, and surgical systems across more than 190 countries.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.